tbuckley/cabot-search huggingface dataset:
Endoscopic Ultrasonographic and Clinicopathological Features of Gastric Inflammatory Fibroid Polyps
Authors: Lin Chun-Jung
Journal: Endoscopy (2011)

Background: Inflammatory fibroid polyp (IFP) is a rare benign gastrointestinal subepithelial lesion with an uncertain origin and natural history. Although it is frequently seen in the stomach, histologic diagnosis is difficult without surgical or endoscopic resection. The endoscopic ultrasonographic (EUS) characteristics of IFPs were sporadically reported on imaging tips or small case series study (Matsushita M). However the differenzial diagnosis and optimal treatment of gastric IFP is still a challenge to in-experienced gastroenterologists.
Abstract 4097: Protein tyrosine phosphatase SHP-2 regulates human pancreatic cancer cell biology on collagen I
Authors: Sarah Connelly, Beth A. Isley, Cheryl H. Baker, Justin M. Summy
Journal: Cancer Research (2010)

Abstract With a five year survival rate of less than 5%, pancreatic cancer stands as one of the deadliest human malignancies. There is a great need for novel therapeutic strategies for this illness, and improving our understanding of pancreatic cancer biology will be a key step in developing these therapies. The purpose of these studies is to investigate the regulation and function of the Src Homology 2 (SH2) domain containing protein tyrosine phosphatase SHP-2 in human pancreatic cancer cells and to determine its potential value as a therapeutic target for this disease. In other cellular systems, SHP-2 is crucial for integrin and receptor tyrosine kinase-mediated activation of diverse signaling pathways, regulating many of the cellular events necessary for oncogenesis, including cell division, motility, adhesion, and survival. We hypothesized that inhibition of SHP-2 function would negatively impact integrin-mediated cell signaling and biology in response to the extracellular matrix protein collagen I, an abundant component of pancreatic tumor stroma in vivo. Initial results demonstrate that SHP-2 expression and tyrosine phosphorylation/activity are elevated in pancreatic cancer cells, relative to immortalized normal human pancreatic cells. Phosphorylation of SHP-2 is further elevated in the presence of collagen I. SHP-2 tyrosine phosphorylation in pancreatic cancer cells occurrs in a Src family kinase-dependent fashion. Initial results using miRNA-mediated knock-down of SHP-2 expression indicate the importance of SHP-2 for the ability of pancreatic cancer cells to proliferate, migrate and heal cell culture wounds on collagen I. Additionally, SHP-2 knockdown cells grown on collagen I demonstate altered tyrosine phosphorylation patterns of several signal transduction proteins, including focal adhesion kinase (FAK), in comparison to controls. These data suggest, for the first time, an importance for SHP-2 in pancreatic cancer cell biology and the potential value of SHP-2 as a therapeutic target for this disease. Ongoing and future experiments will compare the effects of SHP-2 inhibition on pancreatic tumor growth in vivo. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4097.
Comparison of Single-dose and Intermittent Levosimendan Infusion in Patients With Acute Exacerbation of Advanced Heart Failure
Authors: Abdurrahman Tasal, Mesut Demir, Mehmet Kanadasi, Durmus Yıldıray Sahin, Rabia Akilli Eker, Ahmet Bacaksiz, Mehmet Akif Vatankulu, Abdi Bozkurt, Esmeray Acarturk
Journal: Journal of the American College of Cardiology (2013)
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Authors: Vincent Ribrag, Serge Koscielny, Jacques Bosq, Thibaut Leguay, Olivier Casasnovas, Luc-Mathieu Fornecker, Christian Recher, Hervé Ghesquieres, Franck Morschhauser, Stéphane Girault, Steven Le Gouill, Mario Ojeda-Uribe, Clara Mariette, Jerome Cornillon, Guillaume Cartron, Veronique Verge, Catherine Chassagne-Clément, Hervé Dombret, Bertrand Coiffier, Thierry Lamy, Hervé Tilly, Gilles Salles
Journal: The Lancet (2016)
ELECTRICAL MYOSTIMULATION IMPROVES QUALITY OF LIFE, LEFT VENTRICULAR FUNCTION AND PEAK OXYGEN CONSUMPTION IN PATIENTS WITH CHRONIC HEART FAILURE: RESULTS FROM THE EMS STUDY COMPARING DIFFERENT STIMULATION STRATEGIES
Authors: Frank Van Buuren, Andreas Fründ, Nikola Bogunovic, Dieter Horstkotte, Klaus-Peter Mellwig
Journal: Journal of the American College of Cardiology (2016)
123I Accumulation in Thoracic Neoesophagus Masking Residual Papillary Thyroid Cancer
Authors: Tatianie Jackson, Nathanael Sabbah, Andrei Iagaru
Journal: Clinical Nuclear Medicine (2014)

A 56-year-old woman with prior esophageal resection and reconstruction after accidental lye ingestion presented for management of recently diagnosed thyroid cancer. She had total thyroidectomy with pathology demonstrating bilateral well-differentiated papillary thyroid cancer measuring up to 1.0 cm and positive margins. Approximately 1 month after surgery, I whole-body scan was obtained. Planar images demonstrated linear I uptake in the thorax, compatible with accumulation in the neoesophagus. Given the patient's postsurgical anatomy, SPECT/CT of the thorax was done and demonstrated additional focal I uptake in the left lower neck, compatible with residual thyroid tissue versus thyroid cancer (lymph node metastasis).
Death Takes a Weekend
Authors: Perri Klass
Journal: New England Journal of Medicine (2015)

Interview with Dr. Perri Klass on experiencing weekends in the hospital from a patient's point of view. (10:19)Download Doctors know that weekends in the hospital are harder and slower; things don't necessarily get done. But when you're sick and scared, it can be shocking to discover repeatedly the ways in which that's true. A sick person's calendar takes no notice of days of the week.
BM-32 * CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL
Authors: A. Shaw, R. Mehra, D. S. W. Tan, E. Felip, L. Q. M. Chow, D. Ross Camidge, J. Vansteenkiste, S. Sharma, T. De Pas, G. J. Riely, B. J. Solomon, J. Wolf, M. Thomas, M. Schuler, G. Liu, A. Santoro, M. Geraldes, P. Sen, A. J. Boral, A. Yovine, D.-W. Kim
Journal: Neuro-Oncology (2014)

BACKGROUND: Ceritinib is an ALK inhibitor (ALKi) recently approved for patients with ALK+ advanced NSCLC. Efficacy and safety were evaluated in a subset of patients with BM in the phase I ASCEND-1 study. In 246 patients with ALK+ NSCLC who received ceritinib 750 mg/day, overall response rate (ORR) was 58.5% (95% CI: 52.1, 64.8) and was 66.3% (55.1, 76.3) and 54.6% (46.6, 62.4) in ALKi-naïve and ALKi-treated patients, respectively. METHODS: Patients with ALK+ advanced NSCLC and clinically/neurologically stable BM at baseline who received ceritinib 750 mg/day were analyzed for response based on investigator assessment. RESULTS: Among 246 patients, 124 had BM at baseline, including 98 with prior ALKi treatment and 26 who were ALKi-naïve. The BM subset had a median age of 51.0 years; 85.5% with an ECOG PS ≤1; 58.1% Caucasian, 39.5% Asian; median time from NSCLC diagnosis to first ceritinib dose was 20.5 months. Median duration of exposure was 27 weeks. ORR was 54.0% (44.9, 63.0) in the full cohort [50.0% (39.7, 60.3) in ALKi-treated and 69.2% (48.2, 85.7) in ALKi-naïve]. Median DOR was 7.0 mo (5.5, 9.7) for the full subset [6.9 mo (4.8, 8.5) in ALKi-treated and not estimable (NE) in ALKi-naïve]. Median PFS was 6.9 mo (5.4, 8.4) [6.7 mo (4.9, 8.4) and 8.3 mo (4.6, NE) in ALKi-treated and ALKi-naïve]. Measurable target lesions were identified at baseline in 14 patients (10 ALKi-treated, 4 ALKi-naïve). Seven of these patients achieved a response in the brain (4 ALKi-treated, 3 ALKi-naïve) and 3 had stable disease (all ALKi-treated). The most common adverse events (all grades) in all patients and the BM subset were diarrhea (86% vs 79%), nausea (80% vs 82%), and vomiting (60% vs 63%). CONCLUSIONS: Ceritinib has clinically significant durable efficacy in patients with ALK+ NSCLC, including patients with BM, regardless of prior ALKi treatment.
AB0364 Cardiovascular comorbidities are common among greek patients with rheumatoid arthritis: A cross-sectional study
Authors: C. Tsalapaki, C. Hatzara, A. Kandili, A.G. Antoniadis, E. Kyritsi, D. Vassilopoulos
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid arthritis (RA) is associated with increased morbidity and mortality due to cardiovascular diseases. This association may be due to clustering of traditional cardiovascular risk factors among RA patients and/or to the chronic inflammatory disease process. There are limited data regarding the prevalence of these risk factors in Greek patients with RA. <h3>Objectives</h3> To study the prevalence of cardiovascular co-morbidities in RA patients compared to disease controls in Greece. <h3>Methods</h3> 108 patients who met the 1987 American College of Rheumatology classification criteria for RA and were followed in our Department were included in the study (88 females, mean age ± 1 S.D.=65±12 years). One hundred and eight age- and sex-matched patients with osteoarthritis (OA), served as disease controls. Data regarding co-morbid cardiovascular risk factors were recorded after retrospective chart review and compared between groups. <h3>Results</h3> In this cross-sectional study, 39% of RA patients had at least 1, 13% had 2 and 6% had ≥3 co-morbid cardiovascular conditions. Among RA patients, 5% were smokers (p=0.65 vs OA patients), 7% had diabetes mellitus (p=0.28), 5% had dyslipidemia (p=0.16), 6% had coronary artery disease (p=0.07) and 18% hypertension (p=0.88). There was no statistical difference in the prevalence of these cardiovascular co-morbidities between RA and OA patients. <h3>Conclusions</h3> Although Greek RA patients share similar cardiovascular risks with OA patients, it is of great importance that 39% of them had at least one risk factor for cardiovascular disease. These data emphasize the need for aggressive screening and treatment of cardiovascular co-morbidities in RA patients. <h3>Disclosure of Interest</h3> None Declared
PWE-064 Routine post-operative contrast swallows following anti-reflux surgery and hiatus hernia repair: selective use is preferred
Authors: B Alkhaffaf, P Turner, R Date, M Mughal, J Ward, K Pursnani
Journal: Gut (2012)

<h3>Introduction</h3> The routine use of post-operative contrast studies following gastric fundoplication surgery is contentious. This study aimed to determine whether routine contrast studies were more likely to identify significant post-operative complications when compared to their selective use. <h3>Methods</h3> This was a retrospective study of 241 consecutive patients undergoing primary gastric fundoplication. The primary outcome measure was the identification of significant complications (intrathoracic migration, perforation, volvulus or obstruction) by water-soluble contrast swallow that warranted further intervention or immediate reoperation. <h3>Results</h3> Routine contrast studies (Group A) performed in 125 patients identified 6 abnormalities. Of the remaining 116 patients (Group B), 11 underwent selective contrast studies of which one was abnormal. Two patients from Group A underwent immediate reoperation as a result of the contrast study compared to none from group B (p=1.000). One patient from Group A presented 3 days following discharge with an incarcerated hiatus hernia requiring reoperation despite a normal post-operative contrast study. The incidence of radiologically detected abnormalities was greater in patients whose primary indication for surgery was large hiatus hernia compared to those whose surgery was primarily for gastro-oesophageal reflux; however this was not statistically significant (11% vs 2% respectively; p=0.051). <h3>Conclusion</h3> The routine use of contrast studies following gastric fundoplication is unnecessary as it does not identify a greater number of significant acute post-operative complications when compared to the selective use of such investigations. <h3>Competing interests</h3> None declared.
Abstract 1468: Antagonism of platelet-derived growth factor receptor-α as a potential therapeutic for prostate cancer bone metastases
Authors: Mike R. Russell, Qingxin Liu, Hetian Lei, Andrius Kazlauskas, Alessandro Fatatis
Journal: Cancer Research (2010)

Abstract Prostate adenocarcinoma is the second leading cause of cancer death among men, due primarily to the fact that the majority of prostate cancers will eventually spread to the skeleton. Metastatic dissemination requires a complex series of coordinated events that result in cells that escape from the primary tumor into the circulation and eventually colonize distant organs. The ability of disseminated cancer cells to evolve into metastases of clinically significant size depends strongly on their compatibility with, and ability to utilize, this new micro-environment. We previously showed that bone-metastatic prostate cancer cells exposed to human bone marrow respond by activation of cell survival pathways, such as PI3K/Akt., and that these events are mediated by the alpha-receptor for platelet-derived growth factor (PDGFRα). We also have shown that prophylactic antagonism of this receptor using IMC-3G3, a monoclonal, humanized antibody currently in phase II trials, was able to significantly reduce tumor burden in an in vivo model of skeletal metastasis. Here we show that IMC-3G3 can be used in a curative manner to reduce the growth of previously established skeletal lesions. In addition, we have successfully combined this antibody with zoledronic acid, a bisphosphonate commonly used to treat skeletal metastases, with encouraging results. Interestingly, treatment with a monoclonal antibody targeting only host PDGFRα failed to show any significant difference over saline treated mice. Lastly, we sought to dissect the mechanism by which PDGFRα may exert its role within the bone microenvironment. We provide evidence that soluble components of human bone marrow can activate PDGFRα through a mechanism that does not require the canonical binding of PDGF ligand(s) to the receptor. To establish the relevance of this phenomenon in vivo, we employed a PDGFRα mutant lacking the extracellular ligand-binding domain. Our studies show that this truncated PDGFRα was able to restore bone-metastatic potential of prostate cancer cells as effectively as the full-length form of the receptor. In addition, we have found that expression of PDGFRα, and its related signaling events, results in the regulation of a specific set of genes that we believe may aid in the survival and growth of metastatic prostate cancer cells within the bone. Studies to understand the contribution of several of these putative bone metastatic genes are currently underway in our laboratory. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1468.
Incidental Multiple Focal Uptakes of Tc-99m MDP in Both Lungs Without Lung Parenchymal Abnormality
Authors: Seok-Ho Yoon, He-Sung Song, Bong-Hoi Choi, Su Jin Lee, Joon-Kee Yoon, Young-Sil An
Journal: Clinical Nuclear Medicine (2011)

We report a case of incidental multiple focal uptakes of Tc-99m MDP in both the lungs without lung parenchymal abnormality. A 15-year-old girl who had no symptoms or history of pulmonary disorder was referred for Tc-99m MDP bone scintigraphy to evaluate temporomandibular joint disorders. Bone scintigraphy showed multiple focal uptakes in the chest. Single photon emission computed tomography/computed tomography scan performed on the same day showed that abnormal uptakes were located in both the lungs and no abnormalities in the corresponding pulmonary parenchymal sites. Abnormal uptakes resolved on bone scintigraphy after 7 days.
The appropriate dose and cost of iron replacement therapy in patients with IBD
Authors: Rui Dong, Shan Zheng, Gong Chen
Journal: Gut (2016)

We read with great interest the article by Lee et al ,1 who performed an open-label clinical trial to compare the effects of per os (PO) versus intravenous iron replacement therapy (IRT) for iron deficiency in patients with IBD. They concluded that IRT in patients with iron deficiency or anaemia induced significant shifts in bacterial community structure and metabolite landscape in faeces, and PO iron therapy affected the presence of specific molecular bacterial species. These are impressive findings that raise two important issues.

First, Lee et al 1 enrolled participants with Crohn’s disease (n=31), UC (n=22) and non-IBD control anaemic subjects (n=19) for IRT intervention 3 months PO iron sulfate or intravenous iron sucrose. PO participants …
Abstract 4678: Post-diagnosis use of lipophilic statins and breast cancer recurrence: A Danish nationwide cohort study
Authors: Thomas P. Ahern, Lars Pedersen, Deirdre P. Cronin-Fenton, Maja Tarp, Rebecca A. Silliman, Henrik Toft Sørensen, Timothy L. Lash
Journal: Cancer Research (2011)

Abstract Statins may affect non-cardiovascular endpoints, including cancer incidence and survival. These effects may depend on the solubility of the specific medicine. Our objective was to measure the association between post-diagnosis lipophilic and hydrophilic statin use and recurrence among non-metastatic breast cancer patients. We ascertained incident cases of stage I-III invasive breast cancer diagnosed in Denmark between 1996 and 2006 from the Danish Breast Cancer Cooperative Group registry, and linked these records to the Register of Medicinal Products (RMP), which automatically logs pharmacy transactions in Denmark. We determined statin prescriptions filled by cohort members by searching the RMP for appropriate ATC codes. Statins were classified by solubility (Table 1) and exposure status was updated yearly. Follow-up began upon completion of primary therapy and continued until the first of breast cancer recurrence, death from any cause, emigration from Denmark, or the end of 2006. Associations were estimated with time-dependent crude and multivariate Cox regression models. We enrolled 18,769 breast cancer patients, with a median follow-up of 6.2 years. Of the 3,282 women ever prescribed a statin after diagnosis, 2,518 were exclusively prescribed lipophilic statins and 210 were exclusively prescribed hydrophilic statins. Crude and multivariate models yielded similar estimates. Lipophilic (but not hydrophilic) statin use was associated with a reduced rate of breast cancer recurrence (compared with no statin use: multivariate HR for lipophilic statin use = 0.65, 95% CI: 0.55, 0.76; multivariate HR for hydrophilic statin use = 0.89, 95% CI: 0.61, 1.3). Associations were similar when estimated in the subset of women with no pre-diagnosis statin exposure. In this population-based prospective cohort study with complete information on prognostic and treatment variables, breast cancer patients who took lipophilic statins had a reduced rate of breast cancer recurrence. (a) Hazard ratios adjusted for age, menopausal status, tumor stage, ER status, adjuvant hormonal therapy, type of surgery, comorbidity, and co-prescription of aspirin. Estimates were similar in models further adjusted for chemotherapy, type of surgery, receipt of radiotherapy, and co-prescription of hormone replacement therapy, NSAIDs, anticoagulants and ACE inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4678. doi:10.1158/1538-7445.AM2011-4678
PTU-194 The Diagnostic Utility of Coeliac Serology in Lymphocytic Duodenosis
Authors: I Aziz, D M Smillie, D S Sanders
Journal: Gut (2013)

<h3>Introduction</h3> Lymphocytic duodenosis (LD) is defined by normal villous architecture and intraepithelial lymphocytes (IELs) &gt; 25 per 100 enterocytes. Such patients should not be diagnosed with coeliac disease (CD), solely by histology, as recent studies have suggested other associations with LD. Coeliac serology (tissue transglutaminase [TTG] and/or endomysial antibodies [EMA]) may play a useful role although their diagnostic value in such settings is unknown. <b>Aims</b>To provide diagnostic outcomes in our expanding cohort of LD patients whilst also assessing the clinical utility of coeliac serology. <h3>Methods</h3> Two hundred patients with LD were investigated for CD and other known associations of LD, by means of revisiting the patient’s history and recent investigations including the initial coeliac serology, followed by a combination of gluten challenge, HLA typing, repeat duodenal biopsies, and exclusion of infection/inflammatory bowel disease. In the absence of an alternative cause, a diagnosis of CD was based on the persistence or progression of LD on a gluten containing diet, the presence of HLA DQ2 or DQ8, and a clinical response to a gluten free diet. <h3>Results</h3> 150 female, 50 male, mean age 49, SD 16, age range 17–83 An identifiable association was found in 70% of patients – with CD (20%), NSAIDs (17%) and H,pylori (16%) accounting for the majority. In 30% no cause was found, although reassuringly 2/3rd normalised their histology. The role of coeliac serology in LD for diagnosing CD is shown in table 1. <h3>Conclusion</h3> As a single test, EMA has a greater diagnostic accuracy than TTG when assessing patients with LD. As a combination test, only the presence of both a positive EMA and a raised TTG has a 100% predictive value for CD. Therefore, although coeliac serology is useful in LD, most cases still require further work-up for diagnostic confirmation. <h3>Disclosure of Interest</h3> None Declared.
In-111 Octreotide Scintigraphy in Adult Medulloblastoma
Authors: ISABEL HERVÁS, ROSA PÉREZ-VELASCO, PILAR BELLO, ANTONIO MATEO
Journal: Clinical Nuclear Medicine (2003)

From the Department of Nuclear Medicine, University Hospital La Fe, Valencia, Spain Received for publication May 13, 2002. Revision accepted October 7, 2002. Correspondence: Isabel Hervás, Department of Nuclear Medicine, University Hospital La Fe, Avda. Campanar 21, 46009 Valencia, Spain. E-mail: [email protected]